December, 2014: Plasma Gelsolin Broad Infectious Disease Patents Granted in Europe, Canada, Hong Kong and Australia

Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria. This adds to our broad geographic coverage, including a patent granted last year in China. BioAegis is pursuing worldwide patent filings for infectious disease.